Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2013 Jun 10;13(5):559–567. doi: 10.1016/j.clml.2013.03.019

Table 3.

Grade ≥3 adverse events occurring in ≥2 patients, by MedDRA preferred term

Barasertib dose + LDAC 400 mg

Adverse event, n (%) 800 mg
(n=6)
1000 mg
(n=13)
1200 mg
(n=3)
Total
(n=22)
  Any grade ≥3 AE* 6 12 3 21 (96)
  Febrile neutropenia 4 9 0 13 (59)
  Neutropenia 1 2 1 4 (18)
  Stomatitis 0 2 2 4 (18)
  Pneumonia 0 3 0 3 (14)
  Anemia 2 0 0 2 (9)
  Diarrhea 1 1 0 2 (9)
  Thrombocytopenia 1 1 0 2 (9)
*

All events are grade 3 except for thrombocytopenia (both grade 4)